CR
Novo Nordisk (NVO) and Eli Lilly (LLY), the undisputed leaders in the global obesity drug market, saw their stocks heading in opposite directions later this week after the former disappointed investors with its next-gen weight loss candidate, CagriSema.
The contrasting